Rhodiola Rosea for Cognitive Function

Verdict: Weak, disputed evidence for cognitive benefit

Rhodiola rosea has only weak, disputed evidence for cognitive function: a handful of small, dated trials hint at better mental performance, but the effect appears driven by reduced fatigue rather than any direct brain-boosting action, and no major health body endorses it for cognition.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade is C (Weak Evidence) because the human trials are few, small, and old. The cognitive signals come almost entirely from anti-fatigue studies in which mental performance was a secondary outcome: night-duty physicians (PMID 11081987), exam-stressed students (PMID 10839209, a pilot), and military cadets (PMID 12725561). A 2011 systematic review (PMID 21036578) judged the effect on mental performance plausible but explicitly flagged a lack of independent replication, and there is no cognition-specific RCT or meta-analysis since 2020.

It is marked Disputed because the apparent benefit is likely fatigue-mediated rather than a true nootropic effect, and one supportive trial (PMID 20374974) tested ADAPT-232, a multi-herb combination, so its attention gains cannot be credited to rhodiola alone. Several trials used the proprietary SHR-5 extract with undisclosed funding, weakening confidence further.

Regulators and clinicians reinforce the cautious read. The UK registers rhodiola only as a traditional herbal product for stress and fatigue based on traditional use, not proven efficacy, and the US FDA has issued warning letters over disease claims. Mayo Clinic and Harvard Health publish nothing supporting rhodiola for memory, and the Alzheimer's Association states that no supplement has been proven to benefit cognitive function or brain health.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.56
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
73%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.562
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Rhodiola rosea in stress induced fatigue - a double blind cross-over study of SHR-5 on mental performance of physicians during night duty
PMID: 11081987 2000 RCT (double-blind) n = 56
Finding: Statistically significant improvement in fatigue index in the SHR-5 group during the first 2-week period vs placebo; no side effects (exact p-value not reported in abstract).
View on PubMed
A double-blind, placebo-controlled pilot study of SHR-5 extract on fatigue of students caused by stress during an examination period
PMID: 10839209 2000 RCT (double-blind) n = 40
Finding: SHR-5 group showed significant improvement in physical fitness, mental fatigue and neuro-motoric tests (p<0.01) and self-assessed well-being (p<0.05) vs placebo.
🟠 Limited quality
View on PubMed
A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work
PMID: 12725561 2003 RCT (double-blind) n = 161
Finding: Both verum groups had higher AFI (1.0385 and 1.0195) vs placebo (0.9046), p<0.001; no meaningful difference between the two doses.
View on PubMed
Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions
PMID: 20374974 2010 RCT (double-blind) n = 40
Finding: ADAPT-232 group showed significantly better attention, speed and accuracy (TN-E scores) vs placebo within 2 hours (p<0.05); minor adverse events in both arms.
🟠 Limited quality
View on PubMed
The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials
PMID: 21036578 2011 系統性回顧
Finding: Concludes R. rosea may have beneficial effects on mental performance; 5 of 10 RCTs scored >3 on Jadad (good quality) but the review stresses a lack of independent replications; no pooled effect size.
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Rhodiola rosea source↗
L4c UK NHS
Neutral
Rhodiola rosea L. is a plant that grows at high altitudes in the arctic areas of Europe, Asia and North America. It is a traditional herbal medicinal product registered in the UK for the treatment of mental and physical symptoms of stress and overwork, such as fatigue, exhaustion and mild anxiety. source↗
L4d TW TFDA / 衛福部
Neutral
紅景天列於食藥署「可供食品使用原料彙整一覽表」,學名包含 Rhodiola sacra、Rhodiola crenulata、Rhodiola rosea L.、Rhodiola sachalinensis,可供食品使用部位為根。臺灣中藥典亦收載紅景天(景天科大花紅景天之乾燥根及根莖),效能為益氣活血、通脈平喘,分類為補益藥(補氣)。 source↗
L5e Specialty Society (condition-mapped)
Not addressed
not a single food, beverage, ingredient, vitamin or supplement has been proven to prevent, treat or cure Alzheimer's disease or to benefit cognitive function or brain health. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-rhodiola-rosea-001 繁體中文版 →